Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
RECRUITING
NCT07265284
PHASE3

A Study to Evaluate Efficacy and Safety of IBI112 in Adolescent Participants With Moderate to Severe Plaque Psoriasis

Sponsor: Innovent Biopharmaceutical Technology (Hangzhou) Co., LTD.

View on ClinicalTrials.gov

Summary

The purpose of this study is to evaluate the efficacy and safety of IBI112 in the treatment of adolescent participants with moderate to severe plaque-type psoriasis.

Official title: A Phase Ⅰ/Ⅲ Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Picankibart in Adolescent Patients With Moderate to Severe Plaque Psoriasis

Key Details

Gender

All

Age Range

12 Years - 18 Years

Study Type

INTERVENTIONAL

Enrollment

104

Start Date

2025-12-03

Completion Date

2029-01-31

Last Updated

2025-12-22

Healthy Volunteers

No

Conditions

Interventions

DRUG

IBI112

IBI112 by subcutaneous injection

DRUG

placebo

placebo by subcutaneous injection

Locations (1)

Beijing Children's Hospital Affiliated to Capital Medical University

Beijing, Beijing Municipality, China